PMDA drug package insert
ネオドパストン配合錠L100
PMDA Prescription drug · 大原薬品工業株式会社 · package insert Sep 27, 2024
Key facts
| Brand names | ネオドパストン配合錠L100, ネオドパストン配合錠L250 |
|---|---|
| Nonproprietary names | レボドパ・カルビドパ水和物 |
| Companies | 製造販売元／大原薬品工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | パーキンソニズム治療剤 |
| Therapeutic category codes | 871169 |
| YJ codes | 1169101F1120, 1169101F2045 |
| Approval numbers | 22100AMX01323, 22100AMX01324 |
| Package insert edition | 第2版 |
| Package insert date | Sep 27, 2024 |
| PMDA document key | 180095_1169101F1120_2 |
| PMDA company code | 180095 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: